0
0
Home » Pharmaceuticals

Asthma – Epidemiology Forecast to 2029

Asthma is a common respiratory condition that affects the lungs. The airways in the lungs narrow and well, causing obstruction to the airflow (CDC, 2013; NHS, 2018). For some people asthma is mild, but in severe cases, people can experience life-threatening asthma attacks (Mayo Clinic, 2018). In most cases, the cause of asthma is unknown, and although there is no cure, medication can help control asthma (CDC, 2013). Asthma can develop at any stage of life. Often, in children, asthma can resolve during their teenage years; however, it is usually a long-term illness, especially if it first develops in adulthood (NHS, 2018).

GlobalData epidemiologists used age- and sex-specific lifetime diagnosed prevalence rates to forecast the lifetime diagnosed prevalent cases. GlobalData epidemiologists applied country-specific lifetime diagnosed prevalence rates of asthma, wherever available, to each country’s population to obtain the number of estimated lifetime diagnosed prevalent cases. Lifetime diagnosed prevalent cases were also segmented by severity of asthma.

The following data describes epidemiology of asthma cases. In 2019, the 7MM had 86,751,036 lifetime diagnosed prevalent cases of asthma. This is expected to increase to 89,414,720 cases by 2029, at an Annual Growth Rate (AGR) of 0.31%. The increase is driven by changes in the in the underlying population structure such as aging and population growth in the 7MM. In 2019, intermittent asthma was the most predominant severity in the 7MM. The US had the highest number of lifetime diagnosed prevalent cases of asthma. The development of more effective therapies, particularly for severe persistent and difficult-to-treat patients, would improve quality of life and reduce the frequency with which patients experience symptoms.

Scope

The Asthma Epidemiology Report and Model provide an overview of the risk factors and global trends of asthma in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

This report also includes a 10-year epidemiological forecast for the following segmentations in all across the 7MM: lifetime diagnosed prevalent cases of asthma; lifetime diagnosed prevalent cases of pancreatic cancer by severity.

The asthma epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

• The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

The Asthma Epidemiology series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global asthma market.

Quantify patient populations in the global asthma market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for asthma therapeutics in each of the markets covered.

Understand magnitude of asthma population by severity.

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Asthma: Executive Summary

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global and Historical Trends

3.4 Forecast Methodology

3.4.1 Sources

3.4.2 Forecast Assumptions and Methods

3.5 Epidemiological Forecast for Asthma (2019–2029)

3.5.1 Lifetime Diagnosed Prevalent Cases of Asthma

3.5.2 Age-Specific Lifetime Diagnosed Prevalent Cases of Asthma

3.5.3 Sex-Specific Lifetime Diagnosed Prevalent Cases of Asthma

3.5.4 Lifetime Diagnosed Prevalent Cases of Asthma by Severity

3.6 Discussion

3.6.1 Epidemiological Forecast Insight

3.6.2 Limitations of Analysis

3.6.3 Strengths of Analysis

4 Appendix

4.1 Bibliography

4.2 About the Authors

4.2.1 Epidemiologist

4.2.2 Reviewers

4.2.3 Global Director of Therapy Analysis and Epidemiology

4.2.4 Global Head and EVP of Healthcare Operations and Strategy

4.3 About GlobalData

4.4 Contact Us

4.5 Disclaimer

List of Tables

Table 1: Summary of Newly Added Data Types

Table 2: Summary of Updated Data Types

Table 3: Risk Factors and Comorbidities for Asthma

List of Figures

Figure 1: 7MM, Lifetime Diagnosed Prevalent Cases of Asthma, N, Both Sexes, All Ages, 2019 and 2029

Figure 2: 7MM, Lifetime Diagnosed Prevalence of Asthma (%), Both Sexes, All Ages, 2009–2019

Figure 3: 7MM, Sources Used for Lifetime Diagnosed Prevalence of Asthma (%)

Figure 4: 7MM, Sources Used for Severity of Asthma (%)

Figure 5: Lifetime Diagnosed Prevalent Cases of Asthma, 7MM, Both Sexes, All Ages, N, 2019

Figure 6: Age-Specific Lifetime Diagnosed Prevalent Cases of Asthma, 7MM, Both Sexes, All Ages, N, 2019

Figure 7: Sex-Specific Lifetime Diagnosed Prevalent Cases of Asthma, 7MM, All Ages, N, 2019

Figure 8: Lifetime Diagnosed Prevalent Cases of Asthma by Severity, 7MM, Both Sexes, All Ages, N, 2019

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2960

Join our mailing list

Saved reports